Table 1.
Patient characteristics
| MELD 6-11 (n = 25) | MELD ≥ 17 (n = 25) | P value | |
| Age, yr (IQR) | 62 (56-69) | 58 (56-66) | 0.58 |
| Male sex, n (%) | 12 (48) | 16 (64) | 0.39 |
| BMI (SD) | 26 (6) | 27 (6) | 0.43 |
| MELD score (IQR) | 8 (7-10) | 22 (19-24) | < 0.0001 |
| Primary disease, n (%) | 0.20 | ||
| NASH | 2 (8) | 4 (16) | |
| Nutritive toxic | 15 (60) | 9 (36) | |
| Hepatitis B | 2 (8) | 2 (8) | |
| Hepatitis C | 5 (20) | 4 (16) | |
| Other | 1 (4) | 6 (24) | |
| Listed for LT, n (%) | 2 (8) | 5 (20) | 0.41 |
| Renal replacement therapy, n (%) | 0 (0) | 2 (8) | 0.49 |
| Anticoagulants, n (%) | 9 (36) | 11 (44) | 0.77 |
| P2Y12–receptor inhibitor | 1 (4) | 0 (0) | |
| ASA | 5 (20) | 8 (32) | |
| LMWH | 3 (12) | 3 (12) | |
| Laboratory parameters | |||
| Bilirubin, mg/dL (SD) | 0.9 (0.5) | 5.7 (4.4) | < 0.0001 |
| Creatinine, mg/dL (SD) | 0.8 (0.19) | 1.9 (1.5) | < 0.0001 |
| Urea, mg/dL (SD) | 28.7 (9.6) | 58.8 (41.6) | < 0.001 |
| INR | 1.1 (0.1) | 1.7 (0.6) | < 0.0001 |
| aPTT, s (SD) | 30 (3.7) | 35 (7.5) | 0.047 |
| Fibrinogen, mg/dL (SD) | 275 (51) | 209 (90) | 0.006 |
| Platelet count, 103/µL (SD) | 145 (51) | 138 (49) | 0.60 |
| Minimum, 103/µL | 80 | 72 | |
| Maximum, 103/µL | 275 | 274 | |
| Thrombocytopenia < 150 × 103/µL, n (%) | 16 (64) | 18 (72) | 1.00 |
Data are given as means except for age which is presented as the median. Data comparisons were made with Mann Whitney U test or χ2 test where applicable. BMI: Body mass index; MELD: Model for end-stage liver disease; NASH: Nonalcoholic steatohepatitis; INR: International normalized ratio; aPTT: Activated partial thromboplastin time; ASA: Acetylsalicylic acid; LMWH: Low-molecular-weight heparin; LT: Liver transplantation; IQR: Indicates interquartile range.